subdermal GLP-1 implants for the treatment of chronic weight management in obese or overweight human patients and type 2 diabetes, respectively,” Mendelsohn added. Vivani has separately ...

We continue to believe that the primary expected advantages of our proprietary NanoPortal implant technology, improving medication adherence and medication tolerability, have the potential to ...

NPM-119 refers to the Company’s six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients ...

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam ...

Try it free for 7 days Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal ... than a sham implant control group throughout a 91-day treatment period.

an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic ...

NPM-119 refers to the Company’s six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients ...